Power Law company profile

Exscientia

Biotech & Life Sciences · Oxford, United Kingdom · Founded 2012 · IPO 2021 Unicorn

Applying artificial intelligence and big data processing to accelerate discovery and development of drugs

Valuation

$500M–1B

Latest valuation · 2026

Unlock exact value

Revenue

$10–50M

Latest reported FY

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $1B+ revenueColt · Power Law growth-stage

Investors

18 investors on Exscientia's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Evotec

Series B+ 17 investors entered at this stage

Frontier IP Group

Casdin Capital

GT Technologies

Laurion Capital Management

Marshall Wace

BlackRock

GT Healthcare

Celgene

Novo Seeds

Novo Holdings

SoftBank

Bristol-Myers Squibb

Mubadala Capital

University of Dundee

SoftBank Vision Fund

Farallon Capital Management

Pivotal Life Sciences

Exscientia mafia

Startups founded by Exscientia alumni

Former Exscientia employees who went on to start their own companies. Sorted by Dealroom signal score.

Myricx BioEst. 2019

Andrew BellUnited Kingdom

Signal score90

Graph TherapeuticsEst. 2024

Gregory VladimerAustria

Signal score83

CHARM TherapeuticsEst. 2021

Laksh AithaniUnited Kingdom

Signal score63

Affinia TherapeuticsEst. 2019

Rob Johnson.United States

Signal score62

DaltontxEst. 2024

GPGarry PairaudeauUnited Kingdom

Signal score48

Outpost BioEst. 2025

JYJenny YangUnited States

Signal score45

Book a demo to explore the full alumni network →

Global footprint

Where Exscientia has talent and traffic

AI talent share

17.6% of workforce is AI talent
(9 of 51 staff)

Core AI59.8%

Other AI47.84%

Non-AI workforce4282.35%

Workforce by country

9 countries with
team presence

🇬🇧 United Kingdom64.2%

🇦🇹 Austria20.2%

🇸🇪 Sweden4%

🇨🇭 Switzerland2.3%

🇩🇪 Germany2.2%

Top 5 of 9 shown

Web traffic by country

490 monthly visits
across markets

🇯🇵 Japan81.6%

🇺🇸 United States0%

Top 2 markets shown

Patent intelligence

$8M patent portfolio · 19 active families

Estimated portfolio value

$8M

1.2% of valuation · 34× the top peer Generate Biomedicines ($233k)

19 active patent families

Where Exscientia innovates Chemical compoundBiological organismMedicinal chemistryMolecular biologyCancer research

Where Exscientia concentrates vs peers

Each axis is a top-10 topic across Exscientia and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Exscientia

An AI-synthesized read of the highest-engagement posts about Exscientia on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Exscientia on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles